RxDoctor Payments Data

Katherine Schaub

Family · Phoenix, AZNPI 1538686654

Payments from drug & device makers

$3,830in general payments, 2019–2025

Across 163 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Viiv Healthcare Company$455
  • Merck$366
  • Johnson & Johnson$326
  • Hologic Sales And Service, LLC$175
  • Novo Nordisk$143
  • plus $618 from 12 others

What the payments were for

  • Food & beverage$3,73197%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,830 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$6,560
Medicare patients
30
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DescovyEmtricitabine/Tenofov Alafenam38$113,696
BiktarvyBictegrav/Emtricit/Tenofov Ala16$73,861
TivicayDolutegravir Sodium13$30,480
OzempicSemaglutide13$14,082
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,396
Albuterol Sulfate HfaAlbuterol Sulfate21$443
ValacyclovirValacyclovir Hcl15$393
Doxycycline Hyclate29$297
Fluticasone Propionate24$294
Amlodipine Besylate24$258
Hydrochlorothiazide17$162
Omeprazole16$149
Rosuvastatin Calcium19$144
Atorvastatin Calcium16$133
Losartan Potassium11$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadDescovy, Biktarvy$1,748$187,55654 claims
Viiv Healthcare CompanyTivicay$455$30,48013 claims
Novo NordiskOzempic$143$14,08213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →